4D Molecular Therapeutics Inc Working Capital to Net Assets Ratio
4D Molecular Therapeutics Inc working capital to net assets ratio. 4D Molecular Therapeutics Inc (FDMT) has a Working Capital to Net Assets ratio of 73.0% as of December 2025. Working capital of $369.15 Million (current assets of $413.13 Million minus current liabilities of $43.98 Million) is measured against net assets of $505.66 Million. A higher ratio indicates strong short-term liquidity financed by the equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of 4D Molecular Therapeutics Inc (2017–2025)
Working capital to net assets ratio of 4D Molecular Therapeutics Inc from 2017 to 2025. This chart shows how 4D Molecular Therapeutics Inc's Working Capital to Net Assets ratio has evolved across 9 annual periods from 2017 to 2025. As of December 2025, the ratio stands at 73.0%, reflecting working capital of $369.15 Million against net assets of $505.66 Million USD. Explore 4D Molecular Therapeutics Inc (FDMT) long-term investment share to see how much of total assets are deployed in long-term investments.
4D Molecular Therapeutics Inc Working Capital to Net Assets Ratio by Year (2017–2025)
4D Molecular Therapeutics Inc working capital to net assets ratio by year from 2017 to 2025. The table below presents the year-by-year Working Capital to Net Assets ratio for 4D Molecular Therapeutics Inc from 2017 to 2025, covering 9 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see FDMT total asset value.
| Year | WC/NA Ratio | Working Capital (USD) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 73.0% | $369.15 Million | $505.66 Million | $413.13 Million | $43.98 Million | ▼ -6.5 pp |
| 2024 | 79.5% | $405.78 Million | $510.61 Million | $434.93 Million | $29.15 Million | ▼ -10.7 pp |
| 2023 | 90.2% | $277.64 Million | $307.83 Million | $296.59 Million | $18.95 Million | ▲ +1.7 pp |
| 2022 | 88.5% | $204.78 Million | $231.34 Million | $220.51 Million | $15.73 Million | ▲ +13.3 pp |
| 2021 | 75.2% | $239.94 Million | $319.11 Million | $256.28 Million | $16.34 Million | ▼ -28.5 pp |
| 2020 | 103.7% | $265.91 Million | $256.39 Million | $282.66 Million | $16.74 Million | ▲ +157.9 pp |
| 2019 | -54.2% | $39.55 Million | $-72.97 Million | $52.51 Million | $12.96 Million | ▲ +257.6 pp |
| 2018 | -311.8% | $86.01 Million | $-27.59 Million | $94.07 Million | $8.05 Million | ▼ -216.9 pp |
| 2017 | -94.9% | $18.59 Million | $-19.59 Million | $24.50 Million | $5.91 Million | — |